Brentuximab vedotin plus chemotherapy for patients with previously untreated, Stage III or IV classical Hodgkin lymphoma: 5-year update of the phase 3 ECHELON-1 study (NCT01712490) Meeting Abstract
| Authors: | Radford, J.; Dlugosz-Danecka, M.; Connors, J. M.; Illes, A.; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; Bartlett, N. L.; Walewski, J.; Ramchandren, R.; Zinzani, P. L.; Hutchings, M.; Munoz, J.; Kim, W. S.; Advani, R.; Ansell, S. M.; Younes, A.; Gallamini, A.; Liu, R.; Little, M.; Fenton, K.; Fanale, M.; Straus, D. J. |
| Abstract Title: | Brentuximab vedotin plus chemotherapy for patients with previously untreated, Stage III or IV classical Hodgkin lymphoma: 5-year update of the phase 3 ECHELON-1 study (NCT01712490) |
| Meeting Title: | 61st Annual Scientific Meeting of the British Society for Haematology |
| Journal Title: | British Journal of Haematology |
| Volume: | 193 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Apr 25-28 |
| Meeting Location: | Virtual |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2021-04-01 |
| Start Page: | 145 |
| End Page: | 147 |
| Language: | English |
| ACCESSION: | WOS:000645412200190 |
| PROVIDER: | wos |
| PUBMED: | 33928641 |
| DOI: | 10.1111/bjh.17492 |
| Notes: | Meeting Abstract: BSH2021-PO-147 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
